



Lund 29<sup>th</sup> of July 2021

## Spermosens has received grant from EU

**As holder of Seal of Excellence in European Union's Horizon 2020, EU's prestigious program IPA4SME has once again awarded Spermosens the support for expansion and strengthening of its patent portfolio.**

The grant will reimburse up to 75% of the European Patent Office fees for European patent application (up to EUR 2 500), as well as 50% of the patent attorney fees for filing the Patent Application to the European Patent Office (up to EUR 2 000) until March 2022.

*"We are proud holders of the Seal of Excellence, and very grateful for once again being awarded support from EU's prestigious IPA4SME program to support the further expansion and strengthening of our patent portfolio"*, says John Lempert, CEO of Spermosens.

*For further information, please contact:*

John Lempert, CEO

+46 (0)76-311 40 91

[info@spermosens.com](mailto:info@spermosens.com)

### Spermosens AB (publ)

[www.spermosens.com](http://www.spermosens.com)

Spermosens, founded in 2018, develops medical devices for male infertility, to individualize and adapt In Vitro Fertilization treatments. The patent-pending technology is based on the discovery of the JUNO protein in egg cells by two independent research groups. Spermosens' first product, JUNO-Checked, consists of two components: a measuring instrument with associated software, as well as disposable chips. The measuring instrument analyzes the sperm applied to the chip and finds out the binding capacity to the egg cell, which enables an individualized choice of appropriate fertility treatment based on the measured binding capacity.